



### Supplementary Figure 7:

**A** Baseline dynamic adhesion of peripheral blood CD4<sup>+</sup> T cells to MAdCAM-1 at week 0 in patients achieving remission (n = 34) or in non-remission (n = 39) at T5.

**B** Receiver-operator characteristic (ROC) of baseline dynamic adhesion of CD4<sup>+</sup> T cells to MAdCAM-1 for the prediction of remission at T5.

**C** Baseline dynamic adhesion of CD4<sup>+</sup> T cells to MAdCAM-1 and reduction of baseline dynamic adhesion by VDZ treatment *in vitro* in responders (n = 38-39) vs. nonresponders (n = 33-34) to vedolizumab treatment.

**D** Decrease in dynamic adhesion of CD4<sup>+</sup> T cells to MAdCAM-1 from week 0 to week 6 in vedolizumab responders (n = 33) vs. non-responders (n = 30) and in patients achieving remission (n = 29) or not (n = 34).

**E** Correlation of the difference in dynamic adhesion of CD4<sup>+</sup> peripheral blood T cells to MAdCAM-1 between week 0 and 6 with the difference in the abundance of peripheral blood CD4<sup>+</sup> T cells expressing  $\alpha 4\beta 7$  between week 0 and week 6 (n = 56).